
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon is a global market leader in contract research services for the pharmaceutical and biotechnology industries with an expanding pipeline, strong performance in recent quarters, and efficient operations leading to improved margins. The company's commitment to gender equality and targeted investments in technology and laboratory services highlight their focus on long-term growth. With a diverse and experienced board and workforce, Icon is well-positioned for accelerated growth in the coming years.
Bears say
Icon is facing several fundamental reasons for the negative outlook on their stock. Firstly, there is a risk to the Company's financial reporting and forward guidance due to potential restatements or changes in backlog. Secondly, delays or cancellations in delivering clinical trials on time could harm the Company's reputation with clinical study managers and impact its standing. Lastly, while the Company does prioritize and integrate sustainability considerations into its strategy, it remains unclear how this affects executive compensation and could be a potential risk to investor confidence.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares